276 related articles for article (PubMed ID: 29980194)
1. MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma.
Qiang YW; Ye S; Huang Y; Chen Y; Van Rhee F; Epstein J; Walker BA; Morgan GJ; Davies FE
BMC Cancer; 2018 Jul; 18(1):724. PubMed ID: 29980194
[TBL] [Abstract][Full Text] [Related]
2. MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.
Qiang YW; Ye S; Chen Y; Buros AF; Edmonson R; van Rhee F; Barlogie B; Epstein J; Morgan GJ; Davies FE
Blood; 2016 Dec; 128(25):2919-2930. PubMed ID: 27793878
[TBL] [Abstract][Full Text] [Related]
3. TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing.
Reale A; Khong T; Mithraprabhu S; Savvidou I; Hocking J; Bergin K; Ramachandran M; Chen M; Dammacco F; Ria R; Silvestris F; Vacca A; Reynolds J; Spencer A
Leuk Lymphoma; 2021 Feb; 62(2):337-347. PubMed ID: 33131357
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-induced oxidative stress promotes therapy resistance via upregulation of heme oxygenase-1 in multiple myeloma.
Abe K; Ikeda S; Nara M; Kitadate A; Tagawa H; Takahashi N
Cancer Med; 2023 Apr; 12(8):9709-9722. PubMed ID: 36775962
[TBL] [Abstract][Full Text] [Related]
5. Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Song Y; Li S; Ray A; Das DS; Qi J; Samur MK; Tai YT; Munshi N; Carrasco RD; Chauhan D; Anderson KC
Oncogene; 2017 Oct; 36(40):5631-5638. PubMed ID: 28581522
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells.
Fink EE; Mannava S; Bagati A; Bianchi-Smiraglia A; Nair JR; Moparthy K; Lipchick BC; Drokov M; Utley A; Ross J; Mendeleeva LP; Savchenko VG; Lee KP; Nikiforov MA
Leukemia; 2016 Jan; 30(1):104-11. PubMed ID: 26205085
[TBL] [Abstract][Full Text] [Related]
7. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
[TBL] [Abstract][Full Text] [Related]
8. Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2--implications for a combinatorial treatment.
Fristedt Duvefelt C; Lub S; Agarwal P; Arngården L; Hammarberg A; Maes K; Van Valckenborgh E; Vanderkerken K; Jernberg Wiklund H
Oncotarget; 2015 Aug; 6(24):20621-35. PubMed ID: 26036313
[TBL] [Abstract][Full Text] [Related]
9. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
10. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
Besse A; Besse L; Kraus M; Mendez-Lopez M; Bader J; Xin BT; de Bruin G; Maurits E; Overkleeft HS; Driessen C
Cell Chem Biol; 2019 Mar; 26(3):340-351.e3. PubMed ID: 30612952
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism.
Soriano GP; Besse L; Li N; Kraus M; Besse A; Meeuwenoord N; Bader J; Everts B; den Dulk H; Overkleeft HS; Florea BI; Driessen C
Leukemia; 2016 Nov; 30(11):2198-2207. PubMed ID: 27118406
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
[TBL] [Abstract][Full Text] [Related]
13. The power of proteasome inhibition in multiple myeloma.
Guerrero-Garcia TA; Gandolfi S; Laubach JP; Hideshima T; Chauhan D; Mitsiades C; Anderson KC; Richardson PG
Expert Rev Proteomics; 2018 Dec; 15(12):1033-1052. PubMed ID: 30427223
[TBL] [Abstract][Full Text] [Related]
14. Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma.
Yu Z; Wei X; Liu L; Sun H; Fang T; Wang L; Li Y; Sui W; Wang K; He Y; Zhao Y; Huang W; An G; Meng F; Huang C; Yu T; Anderson KC; Cheng T; Qiu L; Hao M
EBioMedicine; 2022 Apr; 78():103950. PubMed ID: 35344764
[TBL] [Abstract][Full Text] [Related]
15. Safety of proteasome inhibitors for treatment of multiple myeloma.
Schlafer D; Shah KS; Panjic EH; Lonial S
Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
[TBL] [Abstract][Full Text] [Related]
16. Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells.
Baranowska K; Misund K; Starheim KK; Holien T; Johansson I; Darvekar S; Buene G; Waage A; Bjørkøy G; Sundan A
Oncotarget; 2016 Oct; 7(43):70845-70856. PubMed ID: 27683126
[TBL] [Abstract][Full Text] [Related]
17. Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.
Leleu X; Martin TG; Einsele H; Lyons RM; Durie BGM; Iskander KS; Ailawadhi S
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):9-22. PubMed ID: 30287200
[TBL] [Abstract][Full Text] [Related]
18. The deubiquitinase USP7 stabilizes Maf proteins to promote myeloma cell survival.
He Y; Wang S; Tong J; Jiang S; Yang Y; Zhang Z; Xu Y; Zeng Y; Cao B; Moran MF; Mao X
J Biol Chem; 2020 Feb; 295(7):2084-2096. PubMed ID: 31822558
[TBL] [Abstract][Full Text] [Related]
19. Identification of primary MAFB target genes in multiple myeloma.
van Stralen E; van de Wetering M; Agnelli L; Neri A; Clevers HC; Bast BJ
Exp Hematol; 2009 Jan; 37(1):78-86. PubMed ID: 19013005
[TBL] [Abstract][Full Text] [Related]
20. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
